Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060654 · ClinicalTrials.gov registry record · Phase 4
SUBLOCADE Rapid Initiation Extension Study
A Phase 4 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT04060654: Completed Phase 4 study, sponsored by Indivior.
NCT04060654 is a Phase 4 study that has completed, run by Indivior. The registered enrollment target is 17 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04060654, a Phase 4 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
Primary Outcome
Study will report the number of participants with the occurrence of any TEAE during the treatment period.
Interventions
- DRUG Sublocade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2020-05-15 |
| Phase | Phase 4 |
What the finished NCT04060654 record still lists
NCT04060654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Sublocade is the first listed.
NCT04060654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04060654 about?
NCT04060654 is a clinical study titled "SUBLOCADE Rapid Initiation Extension Study". A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
What is the current status of trial NCT04060654?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2019-10-21. Estimated completion is 2020-05-15.
What interventions are being tested in trial NCT04060654?
The interventions under investigation include: Sublocade (DRUG).
Who is sponsoring clinical trial NCT04060654?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04060654's enrollment target sits among peer trials
17 1854th of 2000 higher than 132 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI